AYA.AX down 8.79% to A$3.53 on 30 Jan 2026: AI detection rollout is the key insight

AYA.AX stock closed at A$3.53 on 30 Jan 2026 after a -8.79% drop on heavy volume. The fall follows profit-taking after a recent rally and renewed scrutiny of commercial adoption for Artrya Limited’s Salix AI platform. We examine price drivers, valuation metrics and the short to medium term AI commercialisation outlook for Artrya (ASX: AYA) in Australia.

AYA.AX stock: today’s price action and market facts

Artrya Limited (AYA.AX) finished the session at A$3.53, down -8.79% from the previous close of A$3.87. Today’s range was A$3.43 to A$3.82 on volume 1,232,607.00 shares, above the 50-day average volume of 791,530.00. The company has 113,320,000.00 shares outstanding and a market capitalisation of A$423,816,800.00.

The 50-day average price is A$3.96 and the 200-day average is A$2.23, showing the stock is trading above its long-term trend but slightly below the near-term mean. Year high and low are A$5.24 and A$0.56 respectively.

AYA.AX stock: financials, ratios and valuation signals

Artrya reports EPS of -0.18 and a negative PE of -20.78, reflecting current losses as R&D and commercialisation continue. Key valuation ratios include price to book 18.10, price to sales 15136.31, and EV of A$413,108,800.00 which imply a premium on limited revenue today.

Balance sheet metrics look conservative with debt to equity 0.03 and a strong current ratio 8.27. Cash per share is 0.11, while free cash flow per share is -0.14, underscoring ongoing cash burn as Artrya scales Salix deployments.

AYA.AX stock: product, commercial progress and sector context

Artrya’s Salix AI automates detection of coronary artery disease from CT angiography. Adoption and payer acceptance in hospitals and imaging centres remain the primary commercial levers for revenue growth. Healthcare sector averages show higher PEs; Artrya sits outside traditional metrics because it is early-stage AI healthcare with limited revenue today.

The broader Healthcare sector on the ASX has an average PE of 33.65 and average PB near 5.39, which highlights Artrya’s divergence from peers until revenue scales. Regulatory clearance, reimbursement and clinic validation are immediate operational catalysts.

AYA.AX stock: technicals and trading signals

Momentum indicators show short-term strength mixed with overbought signals. RSI is 70.89 (overbought) and ADX is 40.86 indicating a strong trend. MACD is positive with MACD 0.40 and signal 0.32, but Money Flow Index at 82.92 warns of high buying pressure that could reverse.

Bollinger band middle is 4.20 with a lower band at 3.23, suggesting today’s close near the lower band after profit taking. Traders should note ATR 0.32 for intraday risk sizing.

AYA.AX stock: risks, opportunities and AI strategy

Opportunities: scalable cloud deployment of Salix, recurring software revenue, and cross-sell into cardiology imaging networks. Meyka AI notes AI adoption could materially lift margins if clinical pathways and reimbursement follow.

Risks: execution on commercial contracts, elongated sales cycles in healthcare, regulatory delays, and high research and development spend. The company’s negative margins and AC-driven cash burn mean funding risk if revenue does not accelerate.

AYA.AX stock: Meyka grade and forecast model

Meyka AI rates AYA.AX with a score out of 100: Score 59.26 | Grade C+ | Suggestion: HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus.

Meyka AI’s forecast model projects a monthly target A$4.06, quarterly A$6.10 and yearly A$7.30. Compared to the current price A$3.53, the model implies a 1-month upside of 15.01%, a 3-month upside of 72.78%, and a 12-month upside of 106.84%. Forecasts are model-based projections and not guarantees.

Final Thoughts

Key takeaways: AYA.AX stock closed at A$3.53 on 30 Jan 2026 after a -8.79% drop that reflected short-term profit-taking and a pause in the recent rally. The shares trade above the 200-day average but below the 50-day mean, showing mixed momentum. Valuation remains stretched on forward multiples given limited revenue, with price to book 18.10 and negative PE -20.78. Meyka AI rates Artrya C+ (59.26) and flags execution and commercialization as the dominant risks. Our model projects A$7.30 in 12 months, implying ~106.84% upside from today’s close, but that relies on scalable Salix adoption and steady funding. Investors focused on AI healthcare should weigh the growth opportunity against high R&D spend and long sales cycles. For more on Artrya’s profile and filings see Artrya website and the company overview at StockAnalysis. Meyka AI provides this data as part of an AI-powered market analysis platform; forecasts are projections not guarantees.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.